Comparison of Bone Quality in Type 2 Diabetic Patients With a Non-diabetic Control Population

Type 2 Diabetes Clinical Trial

— DIABONE  

Official title:

Comparison of Bone Quality in Type 2 Diabetic Patients With a Non-diabetic Control Population

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02797314
• Other study ID #: 69HCL16_0092
• Secondary ID: 2016-A01228-43
• Status: Completed
• Phase: N/A
• Start date: March 28, 2017
• Est. completion date: March 8, 2024

Study information

• Verified date: May 2024
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients with type 2 diabetes have many complications in different organs. These complications are extremely frequent and severe: cardiovascular and renal disease, visual impairment, and, more recently, complications affecting bone such as fractures. Conventional methods for the evaluation of fracture risk are based on the Bone Mineral Density (BMD) or FRAX (algorithm for the prediction of osteoporotic fracture risk) are not sufficient in the context of diabetes. Several metaanalyses have shown that, paradoxically, a higher BMD in patients with type 2 diabetes compared to patients not suffering from this disease, independently of body mass index (BMI). The paradoxal increase in fracture risk, despite a high BMD has led to the hypothesis that diabetes induces a modification of the quality and not the quantity of bone. However, there is a lack of data as to bone quality in patients with type 2 diabetes as studies of bone biopsies from patients with type 2 diabetes are extremely rare.

The objective of the study is to compare bone quality in patients with type 2 diabetes to that in patients who do not suffer from type 2 diabetes: evaluation of vertebral fractures by osteodensitometry, measurement of Trabecular Bone Score (TBS), and analysis of bone quality in biopsies (advanced glycation end products (AGE), contents of bone matrix and analysis of mineralization).

The results will then be correlated with blood/urinary markers with the objective to determine one/several non-invasive biomarkers for bone status in diabetic patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: March 8, 2024
• Est. primary completion date: March 8, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Men and women aged greater than 40 years

• Patients requiring surgery of the lower limb

• With a bone mineral density considered normal (T-score = -2)

• Stage 1, 2, or 3 glomerular filtration rate (> 30 mL/min)

• For diabetic patients the diagnosis will have previously established by an endocrinologist

Exclusion Criteria:

• Subjects treated with drugs known to interfere with bone metabolism, including steroids, anticonvulsants, diuretics, and bisphosphonates

• Patients with severe renal disease (< 30 ml/mn); previous history of caner except skin cancer; myocardial infarction; uncontrolled hypertension; untreated hyperthyroidism; hyperthyroidism; malabsorption; bone metabolism diseases; rheumatoid arthritis or collagen diseases

• Pregnant or lactating woman

• Contraindication to taking tetracycline hydrochloride:

• Known hypersensitivity to antibiotics of the tetracycline family or any of the excipients in the medicine

• Severe chronic renal failure

• Chronic liver failure

• Systemic lupus erythematosus

• Concomitant prescription of retinoid or vitamin A (risk intracranial hypertension)

• Psychiatric pathology seriously hampering understanding

• Difficulty understanding oral French

• Not a beneficiary of a social security scheme

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Type 2 Diabetes

Intervention

Other:
• Bone biopsies
Bone biopsies

Locations

Country	Name	City	State
France	Hôpital Edouard Herriot, Hospices Civisl de Lyon	Lyon

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Bone mineral density	Bone mineral density (BMD) measured by Dual-energy X-ray absorptiometry (DXA)	1 month after patient inclusion
Primary	Vertebral fractures	Presence of vertebral fractures evaluated by Vertebral Fracture Assessment (VFA)	1 month after patient inclusion
Primary	Trabecular Bone Score	Trabecular bone score (TBS) is a analytical tool that performs novel grey-level texture measurements on lumbar spine dual X-ray absorptiometry (DXA) images, and thereby captures information relating to trabecular microarchitecture	1 month after patient inclusion